India Pharma Outlook Team | Saturday, 23 August 2025
Takeda Pharmaceuticals, a Japanese drug manufacturer, is expanding its presence in India by looking into ways to conduct global clinical trials there. The goal is to bring Takeda's innovative therapy launches to the world's most populous country sooner, according to Annapurna Das, General Manager of Takeda India.
"India is a strategic growth market for Takeda, and we are making important long-term investments in innovation and capability building," Das said, also adding Takeda wanted to take advantage of the growing clinical trial environment in India. Takeda is also willing to work with local academia, health providers, and technology partners to build its innovation pipeline.
As part of its growth plan, Takeda plans to incorporate India's research and development ecosystem into its global pipeline, enabling Indian patients to access advanced therapies in oncology, neuroscience, gastrointestinal health, and inflammation. Takeda is expected to roll out important cancer drugs in the Indian market over the next two to three years, including a lung cancer therapy this year.
Also Read: AIOCD Launches Kerala's First Pharma LLP to Boost Healthcare Access
Additionally, Takeda has also partnered recently with vaccine manufacturer, Biological E. to co-develop a dengue vaccine that is pending regulatory approval in India. This year, Takeda started an innovation center in Bengaluru, with the mission of enabling its global digital transformation. The center has 500 staff with expertise in AI, data science, engineering, and design, and will grow to 750 staff.
As India’s clinical trials market is expected to grow to $2 billion by 2030, Takeda’s entry into India is another mark of the increasing global recognition of India as a center for pharmaceutical innovation and healthcare innovation.
